

# **Commercializing Biomarkers in Therapeutic and Diagnostic Applications-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data**

<https://marketpublishers.com/r/CEE1169BC8FMEN.html>

Date: February 2018

Pages: 133

Price: US\$ 3,680.00 (Single User License)

ID: CEE1169BC8FMEN

## **Abstracts**

### **Report Summary**

Commercializing Biomarkers in Therapeutic and Diagnostic Applications-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Commercializing Biomarkers in Therapeutic and Diagnostic Applications industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications worldwide and market share by regions, with company and product introduction, position in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications market

Market status and development trend of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by types and applications

Cost and profit status of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, and marketing status

Market growth drivers and challenges

The report segments the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market as:

*Commercializing Biomarkers in Therapeutic and Diagnostic Applications-Global Market Status & Trend Report 2013...*

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market:  
Regional Segment Analysis (Regional Production Volume, Consumption Volume,  
Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)

Middle East and Africa

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market:  
Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share  
and Trend 2013-2023):

Consumables

Services

Software

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market:  
Application Segment Analysis (Consumption Volume and Market Share 2013-2023;  
Downstream Customers and Market Analysis)

Oncology

Cardiology

Neurology

Others

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market:  
Manufacturers Segment Analysis (Company and Product introduction, Commercializing  
Biomarkers in Therapeutic and Diagnostic Applications Sales Volume, Revenue, Price  
and Gross Margin):

Roche

Merck

Merck

BD

Abbott

Genesys Biolabs(20/20GeneSystems)

Affymetrix  
Agendia  
ALMAC  
Arrayit  
Biocartic  
BG Medicine  
KEGG EXPRESSION Database  
Thermo Fisher  
BGI

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

- 1.1 Definition of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in This Report
- 1.2 Commercial Types of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
  - 1.2.1 Consumables
  - 1.2.2 Services
  - 1.2.3 Software
- 1.3 Downstream Application of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
  - 1.3.1 Oncology
  - 1.3.2 Cardiology
  - 1.3.3 Neurology
  - 1.3.4 Others
- 1.4 Development History of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
- 1.5 Market Status and Trend of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2013-2023
  - 1.5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status and Trend 2013-2023
  - 1.5.2 Regional Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2013-2017
- 2.2 Sales Market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions
  - 2.2.1 Sales Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions
  - 2.2.2 Sales Value of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions
- 2.3 Production Market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions

## 2.4 Global Market Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2018-2023

### 2.4.1 Global Market Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2018-2023

### 2.4.2 Market Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2018-2023

## **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Sales Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Types

### 3.2 Sales Value of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Types

### 3.3 Market Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Types

## **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

### 4.1 Global Sales Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry

### 4.2 Global Market Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

### 5.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Countries

#### 5.1.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales by Countries (2013-2017)

#### 5.1.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2013-2017)

#### 5.1.3 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

#### 5.1.4 Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

#### 5.1.5 Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

5.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Manufacturers

5.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Type (2013-2017)

5.3.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales by Type (2013-2017)

5.3.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2013-2017)

5.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

6.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Countries

6.1.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales by Countries (2013-2017)

6.1.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2013-2017)

6.1.3 Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

6.1.4 UK Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

6.1.5 France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

6.1.6 Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

6.1.7 Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

6.1.8 Spain Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

6.1.9 Benelux Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

6.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Manufacturers

6.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Type (2013-2017)

6.3.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications

Sales by Type (2013-2017)

6.3.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications

Revenue by Type (2013-2017)

6.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications

Market Status by Downstream Industry (2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

7.1 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Countries

7.1.1 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales by Countries (2013-2017)

7.1.2 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2013-2017)

7.1.3 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

7.1.4 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

7.1.5 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

7.1.6 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

7.1.7 Australia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

7.2 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Manufacturers

7.3 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Type (2013-2017)

7.3.1 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales by Type (2013-2017)

7.3.2 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2013-2017)

7.4 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**



## 8.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Countries

### 8.1.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales by Countries (2013-2017)

### 8.1.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2013-2017)

### 8.1.3 Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

### 8.1.4 Argentina Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

### 8.1.5 Colombia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

## 8.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Manufacturers

## 8.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Type (2013-2017)

### 8.3.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales by Type (2013-2017)

### 8.3.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2013-2017)

## 8.4 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Downstream Industry (2013-2017)

# **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

## 9.1 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Countries

### 9.1.1 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales by Countries (2013-2017)

### 9.1.2 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2013-2017)

### 9.1.3 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

### 9.1.4 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status (2013-2017)

## 9.2 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Manufacturers

## 9.3 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Type (2013-2017)



Applications Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales by Type (2013-2017)

9.3.2 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2013-2017)

9.4 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

10.1 Global Economy Situation and Trend Overview

10.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Downstream Industry Situation and Trend Overview

## **CHAPTER 11 COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

11.1 Production Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Major Manufacturers

11.2 Production Value of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Major Manufacturers

11.3 Basic Information of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Manufacturer

11.3.2 Employees and Revenue Level of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

## **CHAPTER 12 COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

12.1 Roche

- 12.1.1 Company profile
- 12.1.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
- 12.1.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Roche
- 12.2 Merck
  - 12.2.1 Company profile
  - 12.2.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
  - 12.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Merck
- 12.3 Merck
  - 12.3.1 Company profile
  - 12.3.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
  - 12.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Merck
- 12.4 BD
  - 12.4.1 Company profile
  - 12.4.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
  - 12.4.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of BD
- 12.5 Abbott
  - 12.5.1 Company profile
  - 12.5.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
  - 12.5.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Abbott
- 12.6 Genesys Biolabs(20/20GeneSystems)
  - 12.6.1 Company profile
  - 12.6.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
  - 12.6.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Genesys Biolabs(20/20GeneSystems)
- 12.7 Affymetrix
  - 12.7.1 Company profile
  - 12.7.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

12.7.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Affymetrix

12.8 Agendia

12.8.1 Company profile

12.8.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

12.8.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Agendia

12.9 ALMAC

12.9.1 Company profile

12.9.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

12.9.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of ALMAC

12.10 Arrayit

12.10.1 Company profile

12.10.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

12.10.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Arrayit

12.11 Biocartic

12.11.1 Company profile

12.11.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

12.11.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Biocartic

12.12 BG Medicine

12.12.1 Company profile

12.12.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

12.12.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of BG Medicine

12.13 KEGG EXPRESSION Database

12.13.1 Company profile

12.13.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

12.13.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of KEGG EXPRESSION Database

12.14 Thermo Fisher

- 12.14.1 Company profile
- 12.14.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
- 12.14.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Thermo Fisher
- 12.15 BGI
  - 12.15.1 Company profile
  - 12.15.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
  - 12.15.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of BGI

## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

- 13.1 Industry Chain of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

- 14.1 Cost Structure Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
- 14.2 Raw Materials Cost Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
- 14.3 Labor Cost Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
- 14.4 Manufacturing Expenses Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

- 16.1 Methodology/Research Approach
  - 16.1.1 Research Programs/Design

16.1.2 Market Size Estimation

16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

16.2.1 Secondary Sources

16.2.2 Primary Sources

16.3 Reference

## I would like to order

Product name: Commercializing Biomarkers in Therapeutic and Diagnostic Applications-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/CEE1169BC8FMEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CEE1169BC8FMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

